Mission Statement, Vision, & Core Values of Better Therapeutics, Inc. (BTTX)

You're looking at Better Therapeutics, Inc. (BTTX), a company that set out to revolutionize care with prescription digital therapeutics (PDT), but what does that ambition truly cost, and what does it mean for their future? Their mission is clear: to revolutionize the treatment of cardiometabolic diseases through innovative prescription software, aiming to improve lives by providing personalized digital treatments for conditions like type 2 diabetes.

But how do you square that lofty goal with the financial reality of a trailing twelve-month (TTM) net loss of -$31.57 million as of late 2025, reflecting the intense capital burn of a clinical-stage biotech transitioning to commercialization? Understanding their core values-Excellence, Care, and Innovation-is defintely key to gauging their long-term impact in a digital therapeutics market projected to reach nearly $91 billion by 2034. Are these values strong enough to overcome the near-term financial hurdles, and how will their strategic focus on behavioral change for cardiometabolic diseases ultimately maximize returns?

Better Therapeutics, Inc. (BTTX) Overview

You're looking for clarity on Better Therapeutics, Inc. (BTTX), a company that pioneered a new class of medicine, but whose financial reality has been turbulent. The direct takeaway is this: the BTTX you knew as a commercial entity closed its doors in early 2024, and its valuable assets were acquired by Click Therapeutics.

Better Therapeutics was founded in 2015, based in San Francisco, California, with a vision to develop Prescription Digital Therapeutics (PDTs)-software-based treatments-to address the root causes of chronic cardiometabolic diseases. Their flagship product, AspyreRx (formerly BT-001), was a first-in-class, FDA-authorized PDT for type 2 diabetes, leveraging cognitive behavioral therapy (CBT) to help patients modify behaviors and improve glycemic control.

The company's focus on the behavioral drivers of disease was innovative, but the commercialization path proved brutal. Following a move to explore strategic alternatives and the termination of all employees in March 2024, the company's core assets, including AspyreRx and the Breakthrough Device Designated candidate BT-004 for metabolic dysfunction-associated steatohepatitis (MASH), were acquired by Click Therapeutics in May 2024. The BTTX stock, now trading on the OTC market, represents a shell of the former operating company.

Here's the quick math: The value was in the intellectual property, not the sales execution.

Financial Performance: The Pre-Sale Reality and 2025 Status

If you're looking for a 2025 fiscal year revenue number, the honest answer is that the BTTX entity trading under that ticker has negligible sales, as its commercial operations ceased in 2024. The last concrete financial data before the wind-down tells a story of high burn and minimal commercial traction.

The company's last publicly reported product sales, from the third quarter of 2023, were a mere $10,000. This minimal revenue was set against a substantial net loss of $13.4 million for the same period. This massive disparity-a net loss 1,340 times greater than product sales-is what ultimately forced the company's hand in early 2024.

What this estimate hides is the total lack of a viable commercial product for the BTTX entity in late 2025. The key products that generated the small revenue, like AspyreRx, are now under the control of Click Therapeutics. The BTTX stock was delisted from Nasdaq, a clear signal of its financial distress and inability to meet listing standards.

• Last reported product revenue (Q3 2023): $10,000.
• Last reported net loss (Q3 2023): $13.4 million.
• 2025 BTTX entity revenue: Effectively zero post-asset sale.

Industry Leadership Through Innovation and Acquisition

Better Therapeutics, Inc. is considered a leader not because of its financial success, but because of the foundational innovation it brought to the digital therapeutics (PDT) space. It was one of the few companies to secure FDA authorization for a PDT in type 2 diabetes, a massive and challenging market.

The company's true leadership moment was creating a portfolio of clinically-validated assets so compelling that a strong competitor, Click Therapeutics, chose to acquire them to accelerate its own move into the cardiometabolic space. This acquisition, which included the FDA-authorized AspyreRx and the Breakthrough Device Designated BT-004, effectively cemented the company's technology as a core component of the industry's future, even if the original corporate structure did not survive.

This is a classic example of a technology-first company whose innovation was ahead of its commercial model. The technology is now being integrated with Click Therapeutics' platform to target the massive obesity and GLP-1 drug market, which is where the real growth opportunity lies. You can find a deeper dive into the stakeholders who saw the value in this technology by Exploring Better Therapeutics, Inc. (BTTX) Investor Profile: Who's Buying and Why?

Better Therapeutics, Inc. (BTTX) Mission Statement

You're looking at the core purpose of a company like Better Therapeutics, Inc. (BTTX), especially as a Prescription Digital Therapeutics (PDT) pioneer. The mission statement isn't just marketing; it's the strategic filter for every dollar spent and every product developed. The company's mission is: to revolutionize the treatment of cardiometabolic diseases through innovative prescription software, dedicated to improving the lives of patients suffering from conditions such as diabetes, obesity, and cardiovascular disease by providing personalized and effective digital therapeutics.

This mission is ambitious, aiming to shift the paradigm from managing symptoms with drugs to treating the root behavioral causes with software. To be fair, this is a tough market, and the company's financial reality-a TTM Net Income of negative $31.57 million as of late 2023, with a tiny market capitalization of about $5.45 thousand in November 2025-shows the massive commercialization challenge in this revolution.

For a deeper dive into the company's background, you can check out Better Therapeutics, Inc. (BTTX): History, Ownership, Mission, How It Works & Makes Money.

Component 1: Revolutionize Treatment (Innovation)

The first core component is the commitment to revolutionize treatment. This speaks directly to the company's core value of Innovation. They aren't just making a better pill; they're replacing the pill with code-specifically, a software-based form of Cognitive Behavioral Therapy (CBT) delivered via a smartphone app.

This is a big bet, and the near-term risk is high, especially after the company announced in March 2024 that it was exploring strategic alternatives, including a wind-down, and voluntarily delisted from Nasdaq. Still, the underlying market opportunity is huge: the broader digital therapeutics market is projected to reach nearly $91 billion by 2034. The innovation lies in addressing the root cause of conditions like type 2 diabetes, which traditional drugs often only manage.

• Shift treatment from symptom management to behavioral change.
• Develop FDA-regulated, software-based solutions.
• Challenge the status quo of cardiometabolic care.

Component 2: Innovative Prescription Software (Excellence)

The second component, focusing on innovative prescription software, is all about Excellence-the quality and rigor required to get software cleared by the FDA as a medical device. Their lead product, AspyreRx (formerly BT-001), is a concrete example of this commitment. It's a prescription digital therapeutic (PDT) for type 2 diabetes.

The proof is in the data. In their pivotal clinical trial, AspyreRx demonstrated a statistically significant decrease in A1c levels compared to the control group at 180 days, with a p-value of just 0.01. That's a defintely strong clinical signal for a software product. This product is designed to be prescribed by physicians and reimbursed like traditional medicines, which is the path to achieving commercial excellence in the healthcare system.

Component 3: Improving the Lives of Patients (Care)

The final, most empathetic component is dedicated to improving the lives of patients. This is the company's moral compass, guided by the core value of Care. The mission explicitly targets patients suffering from common, debilitating conditions: diabetes, obesity, and cardiovascular disease.

The focus here is on delivering personalized and effective digital therapeutics. Personalized care is critical because a one-size-fits-all approach fails when dealing with complex behavioral issues. The entire platform is built on delivering nutritional cognitive behavioral therapy (nCBT) to enable lasting changes in neural pathways of the brain. This is how they aim to move beyond short-term fixes to long-term patient health improvement. With over 51.40% of the stock held by insiders, the management team's financial commitment is heavily tied to the success of this patient-centric mission.

Better Therapeutics, Inc. (BTTX) Vision Statement

You're looking at the strategic intent of Better Therapeutics, Inc. (BTTX) and trying to map it to a 2025 reality. The direct takeaway is that the company's ambitious vision, which aimed to reshape healthcare, is now a case study in commercialization risk, having announced a wind-down of operations and a search for a buyer for its assets in March 2024. The stated vision remains a powerful strategic document, but its 2025 context is purely retrospective.

To be fair, the digital therapeutics (PDT) market is projected to reach nearly $91 billion by 2034, so the market opportunity was real. Still, the company's failure to secure broad payer coverage for its flagship product, AspyreRx, led to a critical cash crunch. This is a crucial lesson for any investor in the prescription digital therapeutic space-FDA authorization doesn't automatically mean revenue.

The Vision: Reshaping Healthcare Through Digital Therapeutics

The company's vision was to reshape healthcare through the power of digital therapeutics (PDTs), moving beyond mere treatment to focus on holistic well-being and a proactive approach to health management. This was an authoritative, forward-looking statement, positioning software as a new class of medicine. The reality, however, is stark: the company's commercial launch of AspyreRx in Q4 2023 did not generate the necessary traction to sustain operations into 2025.

• Vision: Reshape healthcare via digital therapeutics.
• Reality: Announced wind-down and delisting from Nasdaq in March 2024.
• Near-Term Risk: Liquidation or fire-sale of intellectual property.

In the last reported quarter before the wind-down decision, the company's net loss for the quarter ended June 30, 2023, was $7.6 million. With cash and cash equivalents at only $6.2 million on the balance sheet at that time, the runway was clearly too short to reach the vision's lofty goal. This is the quick math that led to the strategic failure.

Mission Focus: Revolutionizing Cardiometabolic Disease Treatment

The mission statement was defintely precise: to revolutionize the treatment of cardiometabolic diseases through innovative prescription software, specifically targeting conditions like diabetes, obesity, and cardiovascular disease. This mission was embodied by AspyreRx, the first FDA-authorized digital behavioral therapeutic device for adults with type 2 diabetes (T2D). The clinical data was strong, showing statistically and clinically significant reductions in A1c at 180 days.

But here's what this strong clinical estimate hid: the lack of commercial reimbursement. Despite the product being available for prescription, the company reported $0.00 in product revenue for all quarters leading up to the wind-down, including Q3 2023. The company intended for AspyreRx to be reimbursed like traditional medicines, but the slow pace of securing broad payer coverage-a systemic issue in the PDT space-proved fatal. The mission was clinically sound, but commercially unviable without a better funding bridge.

Core Value Execution: Innovation and Excellence vs. Cash Runway

The company's core values centered on excellence, care, and innovation. Innovation was proven by securing FDA authorization for AspyreRx through the De Novo pathway, creating a new class of diabetes digital behavioral therapeutic devices. Excellence was demonstrated in the pivotal clinical trial, which showed an average drop in HbA1c by 1.3 percentage points after six months for about half of the participants.

Still, the financial pressure forced the company to implement a 35% workforce reduction in March 2023 to preserve cash runway, a clear sign that the pursuit of excellence was constrained by capital. This shows that in a cash-intensive, highly regulated sector, innovation alone isn't enough; you need a financial framework that can withstand the 12-to-24-month delay in payer adoption. The focus on 'care' for patients was undercut by the inability to keep the business alive to deliver that care. For a deeper dive into the financial health that led to this outcome, you should read Breaking Down Better Therapeutics, Inc. (BTTX) Financial Health: Key Insights for Investors.

Next Step: Finance and Strategy teams should analyze the BTTX case study to model the minimum cash runway required to survive a 24-month payer adoption cycle for any new prescription therapeutic product.

Better Therapeutics, Inc. (BTTX) Core Values

You're looking past the noise of a volatile stock ticker and diving into the core of what drives Better Therapeutics, Inc., and honestly, that's the right move. The company's value system-Excellence, Care, and Innovation-is the real long-term asset, especially in the prescription digital therapeutics (PDT) space where trust and clinical rigor are everything. To be fair, their near-term financial picture is tough, with revenue projected near $0 for the 2025 fiscal year, but their commitment to these values is what's funding their runway, even with a TTM net loss of around $31.57 million as of late 2023. That's the reality of a pre-commercial biotech, but the values show where the money is going.

The mission is clear: to revolutionize the treatment of cardiometabolic diseases through innovative prescription software, which means tackling conditions like diabetes and obesity with personalized, effective digital therapeutics. Let's break down how they map their actions to their words.

Excellence: Clinical Rigor and Regulatory Standards

Excellence, for Better Therapeutics, Inc., isn't about vague corporate goals; it's about achieving the highest clinical and regulatory bar. In the digital health world, that means securing U.S. Food and Drug Administration (FDA) authorization, which they did for AspyreRx (formerly BT-001) in July 2023. That authorization was a massive hurdle, positioning AspyreRx as the first prescription-only digital therapeutic device to treat adults with type 2 diabetes.

They don't stop at initial clearance, though. They continue to generate data, like the subgroup analysis showing that using AspyreRx alongside standard-of-care, including GLP-1 receptor agonists, led to substantially greater clinical improvement than control groups. This focus on verifiable outcomes is key. Here's the quick math on their commitment:

• Achieved FDA authorization for AspyreRx in July 2023.
• Completed enrollment of 1,000 participants in long-term effectiveness programs.
• Maintained a significant R&D spend, even as they shifted to commercialization.

You can't argue with a Class 2 medical device designation-that's defintely a high bar.

Care: Patient Access and Health Equity

The value of Care translates directly into expanding access to their therapy, especially for underserved populations who suffer disproportionately from cardiometabolic diseases. A prescription digital therapeutic (PDT) is only valuable if patients can actually get and use it. Their partnership with the American College of Lifestyle Medicine (ACLM) is a concrete example of this commitment.

This initiative is designed to expand access to AspyreRx across a network of 1,400 Federally Qualified Health Centers (FQHCs) in the US. This is a clear action to address health equity, not just a marketing slogan. Plus, securing a rebate agreement with one of the largest Pharmacy Benefit Managers (PBMs) in the US in early 2024 shows they are working within the complex reimbursement system to make AspyreRx financially accessible. If you're interested in the market dynamics of who is backing this kind of value-driven strategy, you should be Exploring Better Therapeutics, Inc. (BTTX) Investor Profile: Who's Buying and Why?

Innovation: Platform and Pipeline Development

Innovation is baked into the company's business model-they are a software company in the regulated healthcare sector. Their proprietary platform is built to deliver a novel form of cognitive behavioral therapy (CBT) that targets the root causes of cardiometabolic diseases, not just the symptoms. This is a huge shift in the treatment paradigm.

What this means is that the platform itself is the core asset, allowing them to pursue a pipeline of other software-based treatments. Their pipeline includes candidates like BT-002 for hypertension and BT-003 for hyperlipidemia. What this estimate hides, though, is the cost of this innovation. The company was still spending significantly on this long-term vision, with R&D expenses at $1.8 million in the third quarter of 2023, even as they were cutting other operating expenses to manage their cash. They are betting that this platform approach will pay off with a multi-product portfolio. That's a high-risk, high-reward innovation strategy.

Next Step: Finance: Track the number of AspyreRx prescriptions filled through the FQHC partnership by the end of Q1 2026 to gauge the true impact of their 'Care' value.